Literature DB >> 8552217

Oxyradical damage and mitochondrial enzyme activities in the mdx mouse.

E Hauser1, H Höger, R Bittner, K Widhalm, K Herkner, G Lubec.   

Abstract

A number of studies have already been undertaken to investigate involvement of oxyradicals in muscle diseases by means of measurements of oxyradical protective enzymes. We investigated o-tyrosine, which is a biomarker for OH radical damage in vivo, in 10 mdx and 10 control mice. We also measured mitochondrial enzymes in muscle homogenates of 10 mdx and 10 control mice. Mdx mice had significantly elevated values for o-tyrosine, succinat-phenacinmetosulfat oxidoreductase. NADH O2 oxidoreductase and cytochrome C oxidoreductase. Our findings confirm the suggestion that elevated oxyradical production occurs in muscular dystrophies with lack of dystrophin. Furthermore, our results demonstrate that OH radical damage does not impair mitochondrial enzyme activities in the mdx mouse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8552217     DOI: 10.1055/s-2007-979768

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  19 in total

1.  Increased catalase expression improves muscle function in mdx mice.

Authors:  Joshua T Selsby
Journal:  Exp Physiol       Date:  2010-11-01       Impact factor: 2.969

2.  Intracellular energetic units in healthy and diseased hearts.

Authors:  Enn K Seppet; Margus Eimre; Tiia Anmann; Evelin Seppet; Nadezhda Peet; Tuuli Käämbre; Kalju Paju; Andres Piirsoo; Andrei V Kuznetsov; Marko Vendelin; Frank N Gellerich; Stephan Zierz; Valdur A Saks
Journal:  Exp Clin Cardiol       Date:  2005

3.  Between channels and tears: aim at ROS to save the membrane of dystrophic fibres.

Authors:  Carlo Reggiani
Journal:  J Physiol       Date:  2008-04-01       Impact factor: 5.182

4.  Mdx myotubes have normal excitability but show reduced contraction-relaxation dynamics.

Authors:  V Nicolas-Metral; E Raddatz; P Kucera; U T Ruegg
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

Review 5.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

6.  Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion.

Authors:  Stephanie Duguez; William Duddy; Helen Johnston; Jeanne Lainé; Marie Catherine Le Bihan; Kristy J Brown; Anne Bigot; Yetrib Hathout; Gillian Butler-Browne; Terence Partridge
Journal:  Cell Mol Life Sci       Date:  2013-01-24       Impact factor: 9.261

Review 7.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

8.  Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Gavin J Pinniger; Jessica R Terrill; Evanna B Assan; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2017-09-30       Impact factor: 5.182

Review 9.  Wasting mechanisms in muscular dystrophy.

Authors:  Jonghyun Shin; Marjan M Tajrishi; Yuji Ogura; Ashok Kumar
Journal:  Int J Biochem Cell Biol       Date:  2013-05-11       Impact factor: 5.085

Review 10.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.